OHR Pharmaceutical, Inc. (OHRP) Analysts See $-0.07 EPS; 58com (WUBA) Sellers Decreased By 11.96% Their Shorts

February 12, 2018 - By Marguerite Chambers

58com Incorporated (NYSE:WUBA) had a decrease of 11.96% in short interest. WUBA’s SI was 4.04 million shares in February as released by FINRA. Its down 11.96% from 4.59 million shares previously. With 1.15 million avg volume, 4 days are for 58com Incorporated (NYSE:WUBA)’s short sellers to cover WUBA’s short positions. The stock increased 5.20% or $3.53 during the last trading session, reaching $71.35. About 1.73M shares traded or 53.75% up from the average. 58.com Inc. (NYSE:WUBA) has declined 14.06% since February 12, 2017 and is downtrending. It has underperformed by 30.76% the S&P500.

Analysts expect OHR Pharmaceutical, Inc. (NASDAQ:OHRP) to report $-0.07 EPS on February, 13.They anticipate $0.14 EPS change or 66.67% from last quarter’s $-0.21 EPS. After having $-0.08 EPS previously, OHR Pharmaceutical, Inc.’s analysts see -12.50% EPS growth. The stock decreased 5.31% or $0.0163 during the last trading session, reaching $0.2909. About 1.17 million shares traded. OHR Pharmaceutical, Inc. (NASDAQ:OHRP) has declined 77.87% since February 12, 2017 and is downtrending. It has underperformed by 94.57% the S&P500.




Among 3 analysts covering Ohr Pharma (NASDAQ:OHRP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Ohr Pharma had 6 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, October 27 by H.C. Wainwright. On Wednesday, August 10 the stock rating was downgraded by Brean Capital to “Hold”. Brean Capital maintained the stock with “Buy” rating in Friday, August 7 report. The rating was maintained by H.C. Wainwright on Wednesday, August 16 with “Buy”. Roth Capital downgraded OHR Pharmaceutical, Inc. (NASDAQ:OHRP) on Friday, January 5 to “Hold” rating.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. The company has market cap of $16.35 million. The Company’s lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. It currently has negative earnings. The firm is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion.

Investors sentiment increased to 1.44 in Q3 2017. Its up 0.19, from 1.25 in 2017Q2. It is positive, as 3 investors sold OHR Pharmaceutical, Inc. shares while 6 reduced holdings. 6 funds opened positions while 7 raised stakes. 4.60 million shares or 16.87% more from 3.93 million shares in 2017Q2 were reported. State Street accumulated 10,400 shares or 0% of the stock. 417,975 are owned by Blackrock Inc. Geode Cap Mgmt Ltd Liability Corp invested in 0% or 151,120 shares. Sabby Mngmt Ltd reported 0.01% of its portfolio in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Leisure Management holds 64,067 shares or 0.04% of its portfolio. Virtu Finance Ltd Liability invested in 33,345 shares. Hightower Advsr Ltd Co invested in 0% or 27,000 shares. Prelude Cap Mngmt Ltd Llc stated it has 1,100 shares or 0% of all its holdings. Renaissance Ltd Liability Corporation owns 788,409 shares for 0% of their portfolio. Retail Bank Of New York Mellon reported 34,472 shares or 0% of all its holdings. Bryn Mawr invested in 10,000 shares. Vanguard Group has invested 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Pennsylvania-based Pnc Services Gp Incorporated has invested 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Janney Montgomery Scott Limited Liability has 10,500 shares for 0% of their portfolio. Garrison Bradford & Associate owns 0.3% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 497,415 shares.

58.com Inc. operates online classifieds and listing platforms that enable local merchants and clients to connect, share information, and conduct business in China. The company has market cap of $10.45 billion. It primarily operates online multi-content category-classified advertising platforms under the 58 and Ganji names; and Anjuke, an online real estate listing platform. It has a 89.75 P/E ratio. The companyÂ’s platform contains local information of approximately 500 cities or towns in various content categories, including jobs, real estate, used goods, automotive, and yellow pages.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: